Download PDF
Exp Clin Endocrinol Diabetes 2018; 126(06): 342-348
DOI: 10.1055/s-0043-122224
Article
© Georg Thieme Verlag KG Stuttgart · New York

Sex-Dependent Effect of Metformin on Serum Prolactin Levels In Hyperprolactinemic Patients With Type 2 Diabetes: A Pilot Study

Robert Krysiak
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
,
Witold Szkróbka
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
,
Bogusław Okopień
1   Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Katowice, Poland
› Author Affiliations
Further Information

Publication History

29 July 2017
23 November 2017

31 October 2017

Publication Date:
23 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

Background Metformin was found to reduce circulating levels of pituitary hormones.

Objective The purpose of this study was to assess whether sex determines the effect of metformin on lactotroph secretory function.

Methods The study population included 25 women and 12 men with mildly elevated serum prolactin levels (25–75 ng/mL). Because of concomitant type 2 diabetes, all participants were treated with metformin (3 g daily). Plasma levels of glucose and lipids, HOMA1-IR, serum levels of prolactin, thyrotropin and free thyroid hormones, as well as Jostel’s, SPINA-GT and SPINA-GD indices were assessed at baseline and at the end of metformin treatment.

Results The study completed 24 women and 11 men. At baseline, there were no significant differences in circulating levels of glucose and lipids, insulin sensitivity, hormones, Jostel’s, SPINA-GT and SPINA-GD indices between women and men. In both men and women, metformin reduced fasting glucose levels and HOMA1-IR. However, only in women metformin decreased elevated prolactin levels and this effect correlated with an improvement insulin sensitivity, as well as with the impact on SPINA-GT.

Conclusions The results of the study suggest that the effect of metformin on serum prolactin levels is sex-dependent.

Key words

hyperprolactinemia - diabetes - metformin - pituitary hormones
 

  • References

  • 1 American Diabetes Association. Standards of medical care in diabetes – 2017. Pharmacological approaches to glycemic treatment. Diabetes Care 2017; 40 (Suppl. 01) S64-S74
    PubMedGoogle Scholar
  • 2 Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
    CrossrefPubMedGoogle Scholar
  • 3 Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008; 5: 157-167
    CrossrefPubMedGoogle Scholar
  • 4 Vigersky RA, Filmore-Nassar A, Glass AR. Thyrotropin suppression by metformin. J Clin Endocrinol Metab 2006; 91: 225-227
    CrossrefPubMedGoogle Scholar
  • 5 Krysiak R, Okopień B. The effect of metformin on the hypothalamic-pituitary-thyroid axis in women with polycystic ovary syndrome and subclinical hypothyroidism. J Clin Pharmacol 2015; 55: 45-49
    CrossrefPubMedGoogle Scholar
  • 6 Krysiak R, Okopień B. Thyrotropin-lowering effect of metformin in a patient with resistance to thyroid hormone. Clin Endocrinol (Oxf) 2011; 75: 404-406
    CrossrefPubMedGoogle Scholar
  • 7 Krysiak R, Okrzesik J, Okopień B. The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Endocrine 2015; 49: 242-249
    CrossrefPubMedGoogle Scholar
  • 8 Krysiak R, Kowalcze K, Szkróbka W. et al. The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Eur J Intern Med 2016; 30: 94-98
    CrossrefPubMedGoogle Scholar
  • 9 Wu RR, Jin H, Gao K. et al. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 2012; 169: 813-821
    CrossrefPubMedGoogle Scholar
  • 10 Bo QJ, Wang ZM, Li XB. et al. Adjunctive metformin for antipsychotic-induced hyperprolactinemia: A systematic review. Psychiatry Res 2016; 237: 257-263
    CrossrefPubMedGoogle Scholar
  • 11 Billa E, Kapolla N, Nicopoulou SC. et al. Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Gynecol Endocrinol 2009; 25: 427-434
    CrossrefPubMedGoogle Scholar
  • 12 Velija-Ašimi Z. Evaluation of endocrine changes in women with the polycystic ovary syndrome during metformin treatment. Bosn J Basic Med Sci 2013; 13: 180-185
    PubMedGoogle Scholar
  • 13 Banaszewska B, Pawelczyk L, Spaczynski RZ. et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009; 94: 4938-4945
    CrossrefPubMedGoogle Scholar
  • 14 Banaszewska B, Pawelczyk L, Spaczynski RZ. et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011; 96: 3493-3501
    CrossrefPubMedGoogle Scholar
  • 15 Krysiak R, Szkróbka W, Okopień B. Alternative treatment strategies in women poorly tolerating moderate doses of bromocriptine. Exp Clin Endocrinol Diabetes 2017; 125: 360-364
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Krysiak R, Szkróbka W, Okopień B. A neutral effect of metformin treatment on macroprolactin content in women with macroprolactinemia. Exp Clin Endocrinol Diabetes 2016; 125: 223-228
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Fahie-Wilson MN, John R, Ellis AR. Macroprolactin: high molecular mass forms of circulating prolactin. Ann Clin Biochem 2005; 42 Pt 3 175-192
    CrossrefPubMedGoogle Scholar
  • 18 Christian BT, Vandehey NT, Fox AS. et al The distribution of D2/D3 receptor binding in the adolescent rhesus monkey using small animal PET imaging. Neuroimage 2009; 44: 1334-1344
    CrossrefPubMedGoogle Scholar
  • 19 Melnikova V, Orosco M, Calas A. et al. Dopamine turnover in the mediobasal hypothalamus in rat fetuses. Neuroscience 1999; 89: 235-241
    CrossrefPubMedGoogle Scholar
  • 20 Gudelsky GA, Porter JC. Sex-related difference in the release of dopamine into hypophysial portal blood. Endocrinology 1981; 109: 1394-1398
    CrossrefPubMedGoogle Scholar
  • 21 Krysiak R, Szkróbka W, Okopień B. Sex-dependent effect of metformin on hypothalamic-pituitary-thyroid axis activity in patients with subclinical hypothyroidism. Pharmacol Rep 2016; 68: 1115-1119
    CrossrefPubMedGoogle Scholar
  • 22 Chanson P, Borson-Chazot F, Chabre O. et al. Drug treatment of hyperprolactinemia. Ann Endocrinol (Paris) 2007; 68: 113-117
    CrossrefPubMedGoogle Scholar
  • 23 Iván G, Szigeti-Csúcs N, Oláh M. et al. Treatment of pituitary tumors: Dopamine agonists. Endocrine 2005; 28: 101-110
    CrossrefPubMedGoogle Scholar
  • 24 Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of hypopituitarism: Definition and evaluation of the TSH Index. Clin Endocrinol 2009; 71: 529-534
    CrossrefPubMedGoogle Scholar
  • 25 Dietrich JW, Landgrafe-Mende G, Wiora E. et al Calculated parameters of thyroid homeostasis: Emerging tools for differential diagnosis and clinical research. Front Endocrinol (Lausanne) 2016; 7: 57
    PubMedGoogle Scholar
  • 26 Dietrich JW, Müller P, Schiedat F. et al. Nonthyroidal illness syndrome in cardiac illness involves elevated concentrations of 3,5-diiodothyronine and correlates with atrial remodeling. Eur Thyroid J 2015; 4: 129-137
    CrossrefPubMedGoogle Scholar
  • 27 Vilar L, Fleseriu M, Bronstein MD. Challenges and pitfalls in the diagnosis of hyperprolactinemia. Arq Bras Endocrinol Metabol 2014; 58: 9-22
    CrossrefPubMedGoogle Scholar
  • 28 Colao A. Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 2009; 23: 575-596
    CrossrefPubMedGoogle Scholar
  • 29 Chau-Van C, Gamba M, Salvi R. et al. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 2007; 148: 507-511
    CrossrefPubMedGoogle Scholar
  • 30 Long YC, Zierath JR. AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest 2006; 116: 1776-1783
    CrossrefPubMedGoogle Scholar
  • 31 Hekimsoy Z, Kafesçiler S, Güçlü F. et al. The prevalence of hyperprolactinaemia in overt and subclinical hypothyroidism. Endocr J 2010; 57: 1011-1015
    CrossrefPubMedGoogle Scholar
  • 32 López M, Varela L, Vázquez MJ. et al. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 2010; 16: 1001-1008
    CrossrefPubMedGoogle Scholar
  • 33 Ortega-González C, Cardoza L, Coutiño B. et al. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. J Endocrinol 2005; 184: 233-239
    CrossrefPubMedGoogle Scholar
  • 34 Krysiak R, Okrzesik J, Okopień B. Different effects of metformin on the hypothalamic-pituitary-thyroid axis in bromocriptine- and cabergoline-treated patients with Hashimoto's thyroiditis and glucose metabolism abnormalities. Exp Clin Endocrinol Diabetes 2015; 123: 561-566
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Szybiński Z. Polish Council for Control of Iodine Deficiency Disorders. Work of the Polish Council for Control of Iodine Deficiency Disorders, and the model of iodine prophylaxis in Poland. Endokrynol Pol 2012; 63: 156-160
    PubMedGoogle Scholar